Table 2.
Basal clinicopathological characteristics of patients with HCC with and without adjuvant TACE after PSM.
| Variable | Wide margin | Narrow margin | ||||||
|---|---|---|---|---|---|---|---|---|
| No TACE (n =114) |
TACE (n = 114) |
SD | P | No TACE (n = 70) |
TACE (n = 70) |
SD | P | |
| Age, Year | 0.023 | 1.000 | 0.103 | .684 | ||||
| ≤60 | 94 (82.5) | 93 (81.6) | 56 (80.0) | 53 (75.7) | ||||
| >60 | 20 (17.5) | 21 (18.4) | 14 (20.0) | 17 (24.3) | ||||
| Gender | <0.001 | 1.000 | 0.120 | .636 | ||||
| Male | 98 (86.0) | 98 (86.7) | 58 (82.9) | 61 (87.1) | ||||
| Female | 16 (14.0) | 15 (13.3) | 12 (17.1) | 9 (12.9) | ||||
| Diabetes | 0.134 | .756 | 0.049 | 1.000 | ||||
| No | 111(97.3) | 113 (99.1) | 63 (90.0) | 64 (91.4) | ||||
| Yes | 3(2.7) | 1 (0.88) | 7 (10.0) | 6 (8.57) | ||||
| Child-Pugh | <0.001 | 1.000 | — | — | ||||
| A | 113 (99.1) | 113 (99.1) | 70 (100) | 70 (100) | ||||
| B7 | 1 (0.88) | 1 (0.88) | 0 (0) | 0 (0) | ||||
| HBsAg | <0.001 | 1.000 | 0.042 | 1.000 | ||||
| Negative | 16 (14.0) | 16 (14.0) | 10 (14.3) | 9 (12.9) | ||||
| Positive | 98 (86.0) | 98 (86.0) | 60 (85.7) | 61 (87.1) | ||||
| HBV-DNA, IU/mL | 0.022 | 1.000 | 0.183 | .078 | ||||
| ≤2000 | 91 (79.8) | 92 (80.7) | 55 (78.6) | 45 (64.3) | ||||
| >2000 | 23 (20.2) | 22 (19.3) | 15 (21.4) | 25 (35.7) | ||||
| TBIL, μmol/L | 0.168 | .269 | 0.034 | 1.000 | ||||
| ≤17 | 92 (80.7) | 84 (73.7) | 54 (77.1) | 53 (75.7) | ||||
| >17 | 22 (19.3) | 30 (26.3) | 16 (22.9) | 17 (24.3) | ||||
| ALB, g/L | 0.095 | .722 | 0.066 | 1.000 | ||||
| ≤35 | 5 (4.39) | 3 (2.63) | 3 (4.29) | 4 (5.71) | ||||
| >35 | 109 (95.6) | 111 (97.4) | 67 (95.7) | 66 (94.3) | ||||
| ALT, U/L | 0.135 | .383 | 0.167 | .125 | ||||
| ≤44 | 84 (73.7) | 77 (67.5) | 40 (57.2) | 31 (44.3) | ||||
| >44 | 30 (26.3) | 37 (32.5) | 30 (42.8) | 39 (55.7) | ||||
| PT, S | 0.172 | .281 | 0.040 | 1.000 | ||||
| ≤13 | 105 (92.1) | 99 (86.8) | 60 (85.7) | 59 (84.3) | ||||
| >13 | 9 (7.89) | 15 (13.2) | 10 (14.3) | 11 (15.7) | ||||
| NLR | <0.001 | 1.000 | 0.157 | .176 | ||||
| ≤2.5 | 77 (67.5) | 77 (67.5) | 41 (58.6) | 32 (45.7) | ||||
| >2.5 | 37 (32.5) | 37 (32.5) | 29 (41.4) | 38 (54.3) | ||||
| PLT, *109/mL | 0.055 | .835 | 0.090 | .791 | ||||
| ≤100 | 14 (12.3) | 12 (10.5) | 9 (12.9) | 7 (10.0) | ||||
| >100 | 100 (87.7) | 102 (89.5) | 61 (87.1) | 63 (90.0) | ||||
| AFP, ng/mL | 0.175 | .108 | <0.001 | 1.000 | ||||
| ≤400 | 55 (48.2) | 42 (36.8) | 25 (35.7) | 25 (35.7) | ||||
| >400 | 59 (51.8) | 72 (63.2) | 45 (64.3) | 45 (64.3) | ||||
| Type of operation | 0.071 | .688 | 0.059 | .861 | ||||
| Minor | 67 (58.8) | 63 (55.3) | 27 (38.6) | 25 (35.7) | ||||
| Major | 47 (41.2) | 51 (44.7) | 43 (61.4) | 45 (64.3) | ||||
| Transfusion | 0.100 | .614 | 0.106 | .677 | ||||
| No | 104 (91.2) | 107 (93.9) | 54 (77.1) | 57 (81.4) | ||||
| Yes | 10 (8.77) | 7 (6.14) | 16 (22.9) | 13 (18.6) | ||||
| Tumor diameter, cm | 0.019 | 1.000 | 0.059 | .862 | ||||
| ≤5 | 78 (68.4) | 79 (69.3) | 28 (40.0) | 26 (37.1) | ||||
| >5 | 36 (31.6) | 35 (30.7) | 42 (60.0) | 44 (62.9) | ||||
| Microvascular invasion | 0.153 | .315 | 0.116 | .607 | ||||
| Negative | 83 (72.8) | 75 (65.8) | 39 (55.7) | 43 (61.4) | ||||
| Positive | 31 (27.2) | 39 (34.2) | 31 (44.3) | 27 (38.6) | ||||
| Tumor capsule | 0.125 | .420 | 0.064 | .849 | ||||
| Complete | 70 (61.4) | 63 (55.3) | 50 (71.4) | 52 (74.3) | ||||
| Incomplete | 44 (38.6) | 51 (44.7) | 20 (28.6) | 18 (25.7) | ||||
| Edmondson-Steiner grade | 0.112 | .482 | 0.034 | 1.000 | ||||
| I-II | 41 (36.0) | 35 (30.7) | 16 (22.9) | 17 (24.3) | ||||
| III-VI | 73 (64.0) | 79 (69.3) | 54 (77.1) | 53 (75.7) | ||||
| Cirrhosis | 0.020 | 1.000 | 0.032 | 1.000 | ||||
| No | 30 (26.3) | 31 (27.2) | 19 (27.1) | 18 (25.7) | ||||
| Yes | 84 (73.7) | 83 (72.8) | 51 (72.9) | 52 (74.3) | ||||
Bold values indicate statistical significance (P < .05).
Abbreviations: AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; HBV-DNA, hepatitis B virus-deoxyribonucleic acid; HCC, hepatocellular carcinoma; NLR, neutrophil-to-lymphocyte ratio; PLT, platelet; PSM, propensity score matching; PT, prothrombin time; SD, standardized differences; TACE, transcatheter arterial chemoembolization; TBIL, total bilirubin